Virander S Chauhan

Featured in: Favicon

nature.com Favicon

indianexpress.com Favicon

dnaindia.com Favicon

thequint.com Favicon

journalofinfection.com Favicon

Articles

PvDBPII elicits multiple antibody-mediated mechanisms that reduce growth in a Plasmodium vivax challenge trial - npj Vaccines

Jan 5, 2024 | nature.com | Francisco Martinez |Patrick England |Mimi M. Hou |Virander S Chauhan |Simon Draper |Jenny M. Reimer

AbstractThe receptor-binding domain, region II, of the Plasmodium vivax Duffy binding protein (PvDBPII) binds the Duffy antigen on the reticulocyte surface to mediate invasion. A heterologous vaccine challenge trial recently showed that a delayed dosing regimen with recombinant PvDBPII SalI variant formulated with adjuvant Matrix-MTM reduced the in vivo parasite multiplication rate (PMR) in immunized volunteers challenged with the Thai P. vivax isolate PvW1.

Contact details

Emails

[email protected]

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →